PDX Models From EGFR Mutant Tumors

Inclusion Criteria

• •a. Male or female greater than 18 years of age at the time of consent or the age of majority in their residing state.
• •b. Confirmed diagnosis of EGFR mutant NSCLC.
• •1. EGFR T790M patients who have progressed on osimertinib or other third generation (mutant selective) EGFR TKI therapy or
• •2. Patients must have an EGFR exon 19 deletion or L858R and progressed on first line osimertinib or
• •3. Patients with an exon EGFR or HER2 20 insertion mutation.
• •c. A clinically-indicated procedure (required by the patient's treating physician) scheduled no more than 30 calendar days from date of consent.
• •d. A minimum of 21 calendar days between the last dose of systemic therapy and the clinically-indicated procedure is strongly requested but not required\*.
• •e. A minimum of 48 hours between the last dose of an osimertinib therapy or other targeted therapies and the time of the clinically-indicated procedure is strongly requested but not required\*.
• •f. Willingness to undergo all study collection procedures and follow up. g. Provision of written informed consent by the patient. h. Able to communicate (read, write and speak) in English. i. Clinically-indicated procedure to be performed within the US (including Alaska, Hawaii and Puerto Rico), Canada, England, or Israel.
• •\*A treatment washout period is considered best practice for building a PDX from a tumor specimen. However, if this is not medically possible, material may still be accepted to attempt to build a PDX. This may have a significant impact on take rate therefore accepting tumor specimens with no washout period can impact the overall expected take rate of the program.